Story detail view · 2026-07
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more

STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more

Quick Summary

A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular risk

Continue Reading on STAT News

Get instant updates on Telegram

Join our channel to receive the latest headlines and breaking stories as soon as they are published.

Join channel

Comments (0)

Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.

No comments yet. Be the first to share your thoughts!

Write a comment

0 / 500